CacyBP/SIP expression is involved in the clinical progression of breast cancer

World Journal of Surgery

Volumn 34, Issue 11, 2010, Pages 2545-2552

  Wang, Ningju ^a   Ma, Qingyong ^b   Wang, Yinna ^c   Ma, Gang ^a   Zhai, Huihong ^a  

^a AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CACYBP PROTEIN, HUMAN; CALCIUM BINDING PROTEIN; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL; UPREGULATION;

ADULT; AGED; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 79952636241     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-010-0690-2     Document Type: Article

References (32)

1. Kim K, Zang R, Choi SC, Ryu SY, Kim JW (2009) Current status of gynecological cancer in China. J Gynecol Oncol 20(2):72-76
2. Leung GM, Thach TQ, Lam TH, Hedley AJ, Foo W, Fielding R, Yip PS, Lau EM, Wong CM (2002) Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-periodcohort analysis. Br J Cancer 87(9):982-988
3. Yang L, Parkin DM, Ferlay J, Li L, Chen Y (2005) Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14(1):243-250
4. Yang L, Parkin DM, Li L, Chen Y (2003) Time trends in cancer mortality in China: 1987-1999. Int J Cancer 106(5):771-783
5. Kwong A, Cheung P, Chan S, Lau S (2008) Breast cancer in Chinese women younger than age 40: are they different from their older counterparts World J Surg 32(12):2554-2561
6. Olopade OI, Grushko TA, Nanda R, Huo D (2008) Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14(24):7988-7999
7. Tian XS, Cong MH, Zhou WH, Zhu J, Chen YZ, Liu Q (2008) Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie 31(11):610-614
8. Anders C, Carey LA (2008) Understanding and treating triplenegative breast cancer. Oncology (Williston Park) 22(11):1233- 1239 discussion 1239-1240, 1243
9. Schnitt SJ (2003) Benign breast disease and breast cancer risk: morphology and beyond. Am J Surg Pathol 27(6):836-841
10. Filipek A, Wojda U (1996) p30, a novel protein target of mouse calcyclin (S100A6). Biochem J 320(Pt 2):585-587
11. Filipek A, Kuznicki J (1998) Molecular cloning and expression of a mouse brain cDNA encoding a novel protein target of calcyclin. J Neurochem 70(5):1793-1798
12. Matsuzawa S, Li C, Ni CZ, Takayama S, Reed JC, Ely KR (2003) Structural analysis of Siah1 and its interactions with Siah-interacting protein (SIP). J Biol Chem 278(3):1837-1840
13. Filipek A, Michowski W, Kuznicki J (2008) Involvement of S100A6 (calcyclin) and its binding partners in intracellular signaling pathways. Adv Enzyme Regul 48:225-239
14. Ning X, Sun S, Hong L, Liang J, Liu L, Han S, Liu Z, Shi Y, Li Y, Gong W et al (2007) Calcyclin-binding protein inhibits proliferation, tumorigenicity, and invasion of gastric cancer. Mol Cancer Res 5(12):1254-1262
15. Sun S, Ning X, Liu J, Liu L, Chen Y, Han S, Zhang Y, Liang J, Wu K, Fan D (2007) Overexpressed CacyBP/SIP leads to the suppression of growth in renal cell carcinoma. Biochem Biophys Res Commun 356(4):864-871
16. Chen X, Han G, Zhai H, Zhang F, Wang J, Li X, Huang S, Wang X, Fan D (2008) Expression and clinical significance of CacyBP/ SIP in pancreatic cancer. Pancreatology 8(4-5):470-477
17. Zhai H, Shi Y, Jin H, Li Y, Lu Y, Chen X, Wang J, Ding L, Wang X, Fan D (2008) Expression of calcyclin-binding protein/Siah-1 interacting protein in normal and malignant human tissues: an immunohistochemical survey. J Histochem Cytochem 56(8): 765-772
18. Shimizu M, Saitoh Y, Itoh H (1990) Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues. Hum Pathol 21(6):607-612
19. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL, Matsunami N (2001) Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 7(5):927-936
20. Matsuzawa SI, Reed JC (2001) Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 7(5):915-926
21. Shi Y, Hu W, Yin F, Sun L, Liu C, Lan M, Fan D (2004) Regulation of drug sensitivity of gastric cancer cells by human calcyclin-binding protein (CacyBP). Gastric Cancer 7(3): 160-166
22. Yang YJ, Liu WM, Zhou JX, Cao YJ, Li J, Peng S, Wang L, Yuan JG, Duan EK (2006) Expression and hormonal regulation of calcyclin-binding protein (CacyBP) in the mouse uterus during early pregnancy. Life Sci 78(7):753-760
23. Fukushima T, Zapata JM, Singha NC, Thomas M, Kress CL, Krajewska M, Krajewski S, Ronai Z, Reed JC, Matsuzawa S (2006) Critical function for SIP, a ubiquitin E3 ligase component of the beta-catenin degradation pathway, for thymocyte development and G1 checkpoint. Immunity 24(1):29-39
24. Zhai H, Shi Y, Yu J, Hong L, Tang H, Wang J, Hu S, Bai F, Fan D (2006) Establishment and characterization of calcyclin binding protein (CacyBP) monoclonal antibody. Hybridoma (Larchmt) 25(2):91-94
25. Salama I, Malone PS, Mihaimeed F, Jones JL (2008) A review of the S100 proteins in cancer. Eur J Surg Oncol 34(4):357-364
26. Schafer BW, Heizmann CW (1996) The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 21(4):134-140
27. Lee YT, Dimitrova YN, Schneider G, Ridenour WB, Bhattacharya S, Soss SE, Caprioli RM, Filipek A, Chazin WJ (2008) Structure of the S100A6 complex with a fragment from the C-terminal domain of Siah-1 interacting protein: a novel mode for S100 protein target recognition. Biochemistry 47(41):10921- 10932
28. Moog-Lutz C, Bouillet P, Regnier CH, Tomasetto C, Mattei MG, Chenard MP, Anglard P, Rio MC, Basset P (1995) Comparative expression of the psoriasin (S100A7) and S100C genes in breast carcinoma and co-localization to human chromosome 1q21-q22. Int J Cancer 63(2):297-303
29. Wicki R, Franz C, Scholl FA, Heizmann CW, Schafer BW (1997) Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. Cell Calcium 22(4):243-254
30. Maelandsmo GM, Florenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O (1997) Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer 74(4):464-469
31. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M (2002) Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 110(5):633-641
32. Kilanczyk E, Filipek S, Jastrzebska B, Filipek A (2009) CacyBP/ SIP binds ERK1/2 and affects transcriptional activity of Elk-1. Biochem Biophys Res Commun 380(1):54-59